Article Versions Notes

Chesnokov MS, Khan I, Park Y, Ezell J, Mehta G, Yousif A, Hong LJ, Buckanovich RJ, Takahashi A, Chefetz I. The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma. Cancers. 2021; 13(6):1369. https://doi.org/10.3390/cancers13061369

Chesnokov, Mikhail S., Imran Khan, Yeonjung Park, Jessica Ezell, Geeta Mehta, Abdelrahman Yousif, Linda J. Hong, Ronald J. Buckanovich, Akimasa Takahashi, and Ilana Chefetz. 2021. "The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma" Cancers 13, no. 6: 1369. https://doi.org/10.3390/cancers13061369

Chesnokov, M. S., Khan, I., Park, Y., Ezell, J., Mehta, G., Yousif, A., Hong, L. J., Buckanovich, R. J., Takahashi, A., & Chefetz, I. (2021). The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma. Cancers, 13(6), 1369. https://doi.org/10.3390/cancers13061369